HTR2C and X-linked cone dysfunction syndrome with myopia: As described previously [133], pharmacological treatments have been examined for BED including monoamine stimulants; monoamine reuptake inhibitors; 5-HT2C and trace amine receptor agonists; mu opioid, NOP, orexin 1, cannabinoid and receptor antagonists; glutamate N-methyl-D-aspartate receptor antagonists; Sigma1 ligands; and GABAB receptor agonists.